Supriya Lifescience Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company is almost debt free
- Company has a healthy return on capital (ROCE) of 25.1%
- Operating margins have improved to 32.2% from 26.8%
- Company has delivered good sales growth of 16.2% CAGR over last 5 years
- Company generates healthy free cash flow
- Company has a consistent dividend-paying track record
CONS
- Receivables are growing faster than sales - a possible quality concern
- Valuation is stretched - P/E of 37.0 is well above its own 5-year median (22.4)
- Though reporting repeated profits, the company pays out little dividend (3.8%)
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1868.50 | 37.06 | 448315.74 | 0.86 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9482.75 | 86.06 | 251737.22 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4931.90 | 86.01 | 187593.62 | 0.77 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1129.00 | 24.95 | 112618.18 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1368.00 | 32.79 | 110515.04 | 0.95 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1933.25 | 95.54 | 104455.86 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| AUROPHARMA | 1690.00 | 26.19 | 97238.86 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2092.00 | 17.30 | 95660.02 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| DRREDDY | 1143.20 | 29.61 | 95420.61 | 0.70 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| MANKIND | 2266.00 | 45.82 | 93596.02 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2439.55 | 38.29 | 68850.12 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| SUPRIYA | 911.30 | 36.97 | 7334.40 | 0.11 | 24.04 | -30.89 | 189.75 | 30.80 | 25.30 | 25.01 |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 132 | 140 | 140 | 158 | 161 | 166 | 186 | 184 | 145 | 200 | 206 | 277 | 190 | |
| 88 | 108 | 99 | 103 | 98 | 101 | 120 | 117 | 93 | 127 | 134 | 179 | 152 | |
| Operating Profit | 44 | 32 | 41 | 56 | 63 | 65 | 66 | 68 | 52 | 73 | 72 | 98 | 38 |
| OPM % | 33.70% | 22.67% | 29.61% | 35.09% | 38.94% | 38.96% | 35.52% | 36.71% | 35.64% | 36.35% | 34.92% | 35.30% | 20.10% |
| 3 | 2 | 3 | 2 | 2 | 3 | 2 | 3 | 3 | 3 | 2 | 3 | 3 | |
| Interest | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Depreciation | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 6 | 6 | 7 | 7 | 8 | 9 |
| Profit before Tax | 43 | 30 | 40 | 53 | 60 | 62 | 63 | 64 | 47 | 68 | 67 | 92 | 41 |
| Tax % | 33.14% | 19.78% | 25.71% | 30.54% | 25.31% | 25.65% | 25.25% | 21.35% | 26.62% | 26.19% | 25.78% | 19.43% | 41.06% |
| Net Profit | 29 | 24 | 30 | 37 | 45 | 46 | 47 | 50 | 35 | 50 | 50 | 74 | 24 |
| 3.54 | 2.97 | 3.70 | 4.59 | 5.54 | 5.71 | 5.82 | 6.29 | 4.32 | 6.27 | 6.17 | 9.22 | 2.99 |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 184 | 213 | 278 | 312 | 391 | 530 | 461 | 570 | 696 | 828 | 873 | |
| 166 | 191 | 213 | 213 | 218 | 316 | 332 | 395 | 436 | 533 | 592 | |
| Operating Profit | 17 | 22 | 64 | 98 | 173 | 214 | 128 | 176 | 261 | 295 | 280 |
| OPM % | 9.33% | 10.31% | 23.19% | 31.57% | 44.26% | 40.37% | 27.87% | 30.81% | 37.46% | 35.63% | 32.15% |
| 7 | 9 | 8 | 11 | 5 | 8 | 10 | 11 | 10 | 11 | 11 | |
| Interest | 12 | 11 | 10 | 7 | 4 | 4 | 3 | 5 | 2 | 3 | 2 |
| Depreciation | 5 | 5 | 5 | 6 | 7 | 10 | 12 | 16 | 20 | 28 | 31 |
| Profit before Tax | 8 | 14 | 57 | 96 | 167 | 207 | 123 | 166 | 248 | 275 | 268 |
| Tax % | 29.80% | 39.66% | 30.96% | 23.72% | 26.13% | 26.75% | 27.23% | 28.11% | 24.36% | 23.90% | 26.02% |
| Net Profit | 6 | 9 | 39 | 73 | 124 | 152 | 90 | 119 | 188 | 209 | 198 |
| EPS | 3.87 | 1.19 | 5.39 | 10.03 | 16.89 | 18.86 | 11.16 | 14.80 | 23.35 | 25.98 | — |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 19.94% | 3.20% | 3.18% | 5.37% | 5.41% | 4.28% | 3.85% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- 17%
- 5 Years:
- 16%
- 3 Years:
- 22%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- 43%
- 5 Years:
- 11%
- 3 Years:
- 33%
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- 45%
- 1 Year:
- 40%
RETURN ON EQUITY
- 10 Years:
- 31%
- 5 Years:
- 21%
- 3 Years:
- 19%
- Last Year:
- 19%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15 | 15 | 15 | 15 | 15 | 16 | 16 | 16 | 16 | 16 |
| 31 | 40 | 79 | 135 | 254 | 600 | 683 | 799 | 981 | 1,182 | |
| 140 | 121 | 91 | 100 | 89 | 27 | 22 | 5 | 5 | 5 | |
| Trade Payables | 41 | 42 | 44 | 49 | 51 | 49 | 64 | 60 | 75 | 111 |
| 15 | 28 | 24 | 38 | 37 | 44 | 34 | 44 | 41 | 43 | |
| Total Liabilities | 241 | 245 | 253 | 336 | 445 | 735 | 820 | 924 | 1,117 | 1,357 |
| 89 | 91 | 85 | 98 | 100 | 190 | 262 | 310 | 453 | 689 | |
| Capital Work in Progress | 36 | 34 | 35 | 40 | 79 | 43 | 68 | 149 | 148 | 36 |
| 0 | 0 | 0 | 0 | 0 | 0 | 25 | 64 | 63 | 99 | |
| 38 | 32 | 31 | 49 | 72 | 92 | 116 | 85 | 118 | 160 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 112 | 134 | 219 | |
| Cash & Bank | 6 | 3 | 2 | 2 | 89 | 228 | 158 | 75 | 79 | 79 |
| 73 | 85 | 101 | 147 | 105 | 181 | 192 | 129 | 121 | 76 | |
| Total Assets | 241 | 245 | 253 | 336 | 445 | 735 | 820 | 924 | 1,117 | 1,357 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 27 | 31 | 63 | 143 | 106 | 110 | 94 | 113 | 165 | 186 | |
| Cash from Investing | -27 | -5 | 5 | -25 | -47 | -60 | -124 | -174 | -152 | -176 |
| Cash from Financing | -2 | -20 | -50 | -29 | -15 | 150 | -10 | -22 | -8 | -10 |
| -2 | 3 | 4 | 62 | 15 | 139 | -70 | -83 | 4 | -0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-02 - Supriya Lifescience Limited has informed the Exchange about General Updates
2026-09-02 - Supriya Lifescience Limited has informed the Exchange about General Updates
2026-09-02 - Supriya Lifescience Limited has informed the Exchange about Copy of Newspaper Publication
2026-09-02 - The Exchange has sought clarification from Supriya Lifescience Limited for the quarter ended 30-Jun-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: The response of the Company is awaited.
2026-09-01 - Supriya Lifescience Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 24, 2026
2026-08-27 - Supriya Lifescience Limited has informed the Exchange about Copy of Newspaper Publication
2026-08-26 - Supriya Lifescience Limited has informed the Exchange that Record date for the purpose of Dividend is 04-Sep-2026.
2026-08-22 - Supriya Lifescience Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results.
2026-08-18 - Supriya Lifescience Limited has informed the Exchange about Transcript
News
Recent coverage and analyst commentary for SUPRIYA
Loading news…
AI Stock Analyst
Supriya Lifescience Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account